Want to see GB:OXB full AI Analyst Report?

Oxford BioMedica (OXB) Share Forecast & Price Target

112 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

OXB Analyst Ratings

Moderate Buy

2 Buy

1 Hold

0 Sell

Based on 3 analysts giving stock ratings to

Oxford

BioMedica

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

OXB Stock 12 Month Forecast

Average Price Target

774.00 p

▲(35.55% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Oxford BioMedica in the last 3 months. The average price target is 774.00 p with a high forecast of 900.00 p and a low forecast of 595.00 p. The average price target represents a 35.55% change from the last price of 571.00 p.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"463":"463 p","682":"682 p","901":"901 p","572.5":"572.5 p","791.5":"791.5 p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">900.00 p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":774,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">774.00 p</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":595,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">595.00 p</span>\n  </div></div>","useHTML":true}}],"tickPositions":[463,572.5,682,791.5,901],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,560,586.1538461538462,612.3076923076923,638.4615384615385,664.6153846153846,690.7692307692307,716.9230769230769,743.0769230769231,769.2307692307693,795.3846153846154,821.5384615384615,847.6923076923076,873.8461538461538,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,560,576.4615384615385,592.9230769230769,609.3846153846154,625.8461538461538,642.3076923076923,658.7692307692307,675.2307692307693,691.6923076923076,708.1538461538462,724.6153846153845,741.0769230769231,757.5384615384615,{"y":774,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,560,562.6923076923077,565.3846153846154,568.0769230769231,570.7692307692307,573.4615384615385,576.1538461538462,578.8461538461538,581.5384615384615,584.2307692307693,586.9230769230769,589.6153846153846,592.3076923076923,{"y":595,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":464.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":590,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":657,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":618,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":617,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":830,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":645,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":569,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":593,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":623,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":560,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target900.00 p

Average Price Target774.00 p

Lowest Price Target595.00 p

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kane Slutzkin

Deutsche Bank

800 p→595 p

Hold

4.20%

Upside

Downgraded

08/18/26

Oxford Biomedica downgraded to Hold from Buy at Deutsche BankOxford Biomedica downgraded to Hold from Buy at Deutsche Bank

Charles Weston

RBC Capital

1,140 p→900 p

Buy

57.62%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Oxford BioMedica (Other OTC: OXBDF) and Siemens Healthineers AG (Other OTC: SEMHF)

James Vane

Jefferies

827 p

Buy

44.83%

Upside

Reiterated

06/02/26

Jefferies Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)

James Orsborne

Stifel Nicolaus

950 p

Buy

66.37%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)

Zain Ebrahim

J.P. Morgan

400 p→550 p

Hold

-3.68%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451 p

Buy

-21.02%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kane Slutzkin

Deutsche Bank

800 p→595 p

Hold

4.20%

Upside

Downgraded

08/18/26

Oxford Biomedica downgraded to Hold from Buy at Deutsche BankOxford Biomedica downgraded to Hold from Buy at Deutsche Bank

Charles Weston

RBC Capital

1,140 p→900 p

Buy

57.62%

Upside

Reiterated

08/10/26

Analysts Offer Insights on Healthcare Companies: Oxford BioMedica (Other OTC: OXBDF) and Siemens Healthineers AG (Other OTC: SEMHF)

James Vane

Jefferies

827 p

Buy

44.83%

Upside

Reiterated

06/02/26

Jefferies Sticks to Its Buy Rating for Oxford BioMedica (OXBDF)

James Orsborne

Stifel Nicolaus

950 p

Buy

66.37%

Upside

Reiterated

03/11/26

Analysts Offer Insights on Healthcare Companies: vTv Therapeutics (NASDAQ: VTVT) and Oxford BioMedica (Other OTC: OXBDF)

Zain Ebrahim

J.P. Morgan

400 p→550 p

Hold

-3.68%

Downside

Reiterated

12/08/25

Oxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorganOxford Biomedica price target raised to 550 GBp from 400 GBp at JPMorgan

Unknown Analyst

Canaccord Genuity

Not Ranked

Canaccord Genuity

451 p

Buy

-21.02%

Downside

Reiterated

10/07/25

Oxford BioMedica (OXBDF) Receives a Buy from Canaccord Genuity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ODTXOdyssey Therapeutics, Inc.

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

GPCRStructure Therapeutics, Inc. Sponsored ADR

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Oxford BioMedica

3 Months

Charles WestonRBC Capital

Success Rate

15/27 ratings generated profit

Average Return

+4.18%

Copying Charles Weston's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +4.18% per trade.

1 Year

Charles WestonRBC Capital

Success Rate

10/27 ratings generated profit

Average Return

+7.06%

Copying Charles Weston's trades and holding each position for 1 Year would result in 37.04% of your transactions generating a profit, with an average return of +7.06% per trade.

2 Years

Charles WestonRBC Capital

Success Rate

8/27 ratings generated profit

Average Return

-0.40%

Copying Charles Weston's trades and holding each position for 2 Years would result in 29.63% of your transactions generating a profit, with an average return of -0.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

OXB Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, OXB has received 4 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. OXB average Analyst price target in the past 3 months is 774.00.

Each month's total comprises the sum of three months' worth of ratings.

OXB Financial Forecast

OXB Earnings Forecast

Next quarter’s earnings estimate for OXB is -0.28 p with a range of -0.29 p to -0.28 p. The previous quarter’s EPS was -0.05 p. OXB beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Sales Forecast

Next quarter’s sales forecast for OXB is 80.00M with a range of 80.00M to 80.00M . The previous quarter’s sales results were 95.52M . OXB beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year OXB has Performed in-line its overall industry.

OXB Stock Forecast FAQ

What is GB:OXB’s average 12-month price target, according to analysts?

Based on analyst ratings, Oxford BioMedica plc’s 12-month average price target is 774.00.

What is GB:OXB’s upside potential, based on the analysts’ average price target?

Oxford BioMedica plc has 35.55% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Oxford BioMedica plc a Buy, Sell or Hold?

Oxford BioMedica plc has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.

What is Oxford BioMedica plc’s share price target?

The average share price target for Oxford BioMedica plc is 774.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is 900.00 p ,and the lowest forecast is 595.00 p. The average share price target represents 35.55% Increase from the current price of 571 p.

What do analysts say about Oxford BioMedica plc?

Oxford BioMedica plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of Oxford BioMedica plc?

To buy shares of GB:OXB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Oxford BioMedica (OXB) Share Forecast & Price Target

OXB Analyst Ratings

OXB Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Oxford BioMedica

OXB Analyst Recommendation Trends

OXB Financial Forecast

OXB Earnings Forecast

OXB Sales Forecast

OXB Stock Forecast FAQ

Detailed List of Analyst Forecasts